Final logistic regression model for clinical remission at 6months for MTX-exposed subjects
| Predictors | log(OR) | SE of log(OR) | OR | 95%CI for OR | P values |
| Intercept | – | – | – | – | – |
| Age at entry, years | −0.0160 | 0.0124 | 0.98 | 0.96 to 1.01 | 0.1953 |
| Disease duration, years | −0.0105 | 0.0206 | 0.99 | 0.95 to 1.03 | 0.6109 |
| Gender: male versus female | 0.2935 | 0.3697 | 1.34 | 0.65 to 2.77 | 0.4271 |
| Ethnicity: white versus rest | −0.0511 | 0.4137 | 0.95 | 0.42 to 2.14 | 0.9017 |
| DAS28-ESR at baseline | −0.8228 | 0.1600 | 0.44 | 0.32 to 0.60 | <0.0001 |
| Rheumatoid factor positivity: yes versus no | −0.5277 | 0.3214 | 0.59 | 0.31 to 1.11 | 0.1007 |
| MTX use in trial | |||||
| (Randomised to MTX, previous use) versus (not receiving, previous use) | 1.6499 | 0.8252 | 5.21 | 1.03 to 26.2 | 0.0456 |
| Background MTX continued versus (not receiving, previous use) | 0.0126 | 0.7874 | 1.01 | 0.22 to 4.74 | 0.9873 |
| Randomised to or on csDMARD at start: yes versus no | 1.1721 | 0.8953 | 3.23 | 0.56 to 18.7 | 0.1905 |
| On background glucocorticoids at start: yes versus no | 0.1169 | 0.3299 | 1.12 | 0.59 to 2.15 | 0.7230 |
csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28, DiseaseActivity Score 28; ESR, erythrocyte sedimentation rate; MTX, methotrexate.